Year: 2025
Type: review
Abstract: Apolipoprotein E (APOE) is the major lipid transport protein in the brain. Produced primarily by astrocytes and microglia, it delivers cholesterol and other lipids for membrane repair, synaptic maintenance, and immune regulation. Through interactions with specific lipid receptors, APOE maintains neuronal and vascular health. The APOE ε4 allele (APOE4), carried by approximately one-quarter of the population, has an altered protein conformation, which reduces lipid transport efficiency and modifies receptor binding. These changes disrupt lipid homeostasis, increase risk of chronic unresolved neuroinflammation and vascular inflammation, and cause breakdown of the blood–brain barrier (BBB), thus increasing neuronal vulnerability to disease pathology and elevating risk for Alzheimer's disease (AD). In this review, we organize the effects of APOE4 into three interconnected “hits” that modulate disease progression: disrupted lipid handling, neurovascular inflammation, and neuronal dysfunction. These interconnected hits help explain why amyloid- and tau-directed therapies alone have modest success in treating AD, particularly in APOE4 carriers. We review emerging APOE-related therapeutic strategies designed to address these mechanisms directly, including structure correctors to restore normal protein folding, agents that enhance lipidation and receptor-mediated lipid transport, approaches that modulate downstream inflammatory responses, and gene therapies aimed at isoform switching or allele silencing. By aligning therapeutic strategies with specific aspects of APOE4 biology, such approaches have the potential to provide broader and safer benefits, complement existing disease-modifying therapies, and improve outcomes for individuals at heightened genetic risk of AD.
Source: Journal of Neuroscience
Institutions: University of Southern California, Duke University, Duke Medical Center, University of Kentucky, University of California, Los Angeles, University of California System, VA Greater Los Angeles Healthcare System, Greater Los Angeles Geriatric Research Education and Clinical Center, Boston University
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Awards: Sex-Dependent Genetic Landscape of Late-Onset Alzheimer's Disease, Deciphering the regulation of gene expression in the etiology of LOAD, Untangling the diversity in the genetic architecture of late-onset Alzheimer's disease using single cell multi-omics, Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4, Biomarkers of ABCA1 mediated functions in Alzheimers disease, G4572894872, G4611547910, Changing the energy substrate balance: Does APOE2 promote glucose usage to protect from Alzheimer's Disease?, ApoE, ABCA1 and endosomal dysregulation in AD, DHA brain delivery by APOE genotype, A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253, APOE-targeted therapy for precision medicine in late onset Alzheimer's disease: A novel epigenome editing approach for downregulation of APOEe4 expression, CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease, Alzheimer's Abeta, Tau, Apolipoproteins and Blood-brain barrier, The delivery of essential fatty acids to the Brain in Alzheimer's disease, Center of Biomedical Research Excellence in CNS Metabolism, APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease, Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's Disease, Assessing the role of APOE in glial lipid droplet metabolism and function, Microglia targeted interventions in prodromal Alzheimer's disease stage, Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytes, Alzheimer's Disease Research Centers
OpenAlex ID: W4416197064
